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Background: Bleeding is a major obstacle that faces the nasal endoscopiest. The
aim of this study was to evaluate the efficacy and safety of large dose tranexamic
acid (TA) in ensoscopic sinus surgery (ESS) for chronic sinusitis with sinonasal
polyposis.
Patients and Methods: In a double-blinded, prospective, controlled study, 60
patients aged 20-50 years were randomly divided into two equal groups. The
intervention group received (40 mg/kg) TA at induction of anesthesia followed
by continuous infusion at a rate of 1mg/kg/hr. for the whole duration of surgery.
The control group received an equivalent amount of saline as a placebo. The
amount of blood loss, operative time, surgical field quality and complications were
reported.
Results: TA group showed a significant reduction in intraoperative blood loss,
improvement of quality of surgical field and less operative time.
Conclusion: Large dose of TA is safe and effective. It has a positive impact
on reduction of blood loss, operative time and on surgical field quality without
increased risk of complications.
Keywords: Tranexamic acid, Endoscopic sinus surgery, bleeding, chronic
rhinosinusitis with sinonasal polyposis.
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Introduction
Endoscopic sinus surgery (ESS) has become the standard
surgical modality used for treatment of chronic sinusitis. [1]
Bleeding during ESS is a frequently encountered problem
that affects the course and outcome of surgery .Bleeding
impairs clarity of surgical field and increases the rate of
complications. Also, bleeding may increase the duration of
surgery which may affect the general condition of patients
especially patients with associated co-morbidities. [2,3]
Many methods have been employed to minimize bleeding
and to improve visualization during ESS. These techniques
include: the use of local vasoconstrictors, elevation of patient
head, administration of drugs that decrease systemic blood
pressure or heart rate and bipolar cauterization. [4] However,
other alternative measures are required; as, none of these
methods can alone control bleeding and provide satisfactory
surgical field. Of these alternatives is the use of Tranexamic
acid (TA). [5]
TA is a synthetic analogue of amino acid lysine. TA exerts its
antifibrinolytic action through the reversible block of lysine
binding sites on plasminogen molecule. When tissue damage
occurs as a result of any surgical procedure, damaged tissues
release enzymes such as ‘tissue plasminogen activator’. Tissue
plasminogen activator converts plasminogen to plasmin and
fibrinolysis process is activated. TA prevents fibrinolysis
through inhibition of the activity of this enzyme. Many studies
have reported the efficacy of TA in achieving hemostasis
and improving the surgical field quality in orthopedic and
cardiothorathic surgery with minimal or no side effects. [5,6]
In the field of otorhinolaryngology, some studies proved the
beneficial effects of topical and systemic TA in controlling
blood loss and obtaining satisfactory operative field. Up till
now, the extent to which TA can reduce surgical bleeding and

its relationship with the dose of TA remains unclear. [7] The
aim of the current study was to evaluate efficacy and safety
of large dose of TA on reduction of blood loss, operative time
and clarity of surgical field in ESS for CRS with sinonasal
polyposis.
Material and Methods
The current study was conducted after being approved by
the university ethics committee and an informed written
consent was obtained from all patients. The study was
conducted as a double-blind, randomized clinical trial at the
ENT department, Beni Suef university hospital. The study
populations consisted of 60 patients complaining of CRS with
sinonasal polyposis not responding to medical treatment and
were candidates for endoscopic sinus surgery during the
period from February 2016 to June 2017.
Patients were randomly divided into 2 equal groups (30
patients in each group). The intervention group received TA
40 mg as a bolus dose at induction of anesthesia followed
by continuous infusion at a rate of 1mg/kg/hr. for the rest
of surgical procedure. The control group received an equal
amount of normal saline as a placebo.
Patients were enrolled if they had the following criteria:
(a) Patients with CRS with sinonasal polyposis (b) Age
of 18 to 50 years (c) Hemoglobin >10mg/dl (d) Normal
coagulation profile. Patients with the following criteria were
excluded: (a) Patients with CRS without sinonasal polyposis
(b) patients with any other nasal disease rather than CRS (c)
Previous sinus or nasal surgery (d) Having blood diseases or
coagulopathy (e) Patients with hepatic or renal disorders (f)
Patients with systemic comorbidities (g) Patients using anticoagulants or NSAID (h) Allergy to Tranexamic Acid (i) Color
blindness.

Outcomes of large dose Tranexamic acid in endoscopic sinus surgery for chronic sinusitis with sinonasal polyposis, Fawaz, et al

Operative procedures
All patients received oral corticosteroid for 10 days before
surgery to reduce inflammation and lessen intraoperative
bleeding. All operations were done under general inhalational
anesthesia. The anesthesia protocol was the same in both
groups. All patients were operated on by the same surgical
and anesthesia team. The surgical steps were fixed in all
patients. After induction of anesthesia, TA and normal saline
solutions were prepared by an anesthesiologist not involved
in the study protocol. The anesthesiologist in charge and
operating surgeon were not aware of injected drug as the
drug is colorless. The intervention group received TA bolus
(40 mg/kg) then continuous infusion at a rate of (1 mg/kg/
hr.) for the duration of surgery. The control group received an
equal amount of normal saline.
Before start of surgery, a throat pack was inserted to
prevent blood transferring to the gastrointestinal tract. Headup position at level of 30 degrees. All patients underwent
decongestion of the nasal mucosa by local infiltration of 1ml
of epinephrine (1:200,000) in the middle turbinate, inferior
turbinate and agar nasi area. This is followed by application
of nasal pledges soaked in epinephrine (1:200,000) in the
whole nasal cavity.

The surgery was then carried out in the following sequence. At
first, microdebrider was used to clear polyps from both nasal
cavities. After that, Anterior and posterior ethmoidectomy,
middle meatal antrostomy, sphenoid sinusotomy and frontal
sinusotomy were done using cutting forceps and grabbing
instruments.
Primary outcome measures were: (a) Intraoperative blood
loss which was estimated by calculating the collected blood in
a graded suction chamber and reducing the amount of saline
used for washing. The throat pack and nasal pledges used
during surgery were weighted and converted in to ml and
added to blood loss according to Al Kadri. [8] (b) Operative
time was recorded from induction to extubation. (c) Quality of
surgical field was assessed every 15 minutes from the start of
surgery based on Boezzart's scale [9] (Table1) with a scale
from 0 to five. Secondary outcome measures were nausea,
vomiting, impaired color vision within 24 hrs. after surgery.
All patients were packed with Merocell for 24 h. patients were
monitored for surgical complications and drug side effects
as nausea, vomiting, thromboembolic complications, fever or
convulsions and data were recorded.

Table 1 Surgical Field Quality Based on Boezaart’s scale. [9]
Grade

Assessment

No bleeding, cadaveric conditions

0

Slight bleeding, no suction required

1

Slight bleeding, occasional suctioning required

2

Slight bleeding, frequent suctioning required

3

Bleeding threatens surgical field few seconds after suction is removed.
Moderate bleeding, frequent suctioning required

4

Bleeding that threatens surgical field directly after suction is removed
Severe bleeding, constant suctioning required

5

Bleeding appears faster than can be removed by the suction; surgical field severely threatened and surgery usually not
possible

Table 2 Demographic data, duration of surgery and blood loss for both groups

Age (years)

( TA group) (n= 30)

(control group) (n= 30)

P value

35.97±13.53

37.40±12.38

0.670

Sex (male/female)

16/14

22/8

0.090

Net blood loss(ml)

155.50 + 64.93

276.50+ 63.44

<0.001

41.77+9.03

54.93+11.46

<0.001

Operative time(min)

Data are presented as means and standard deviation.

Table 3 Quality of surgical field according to Boezaart scale
Quality of Surgical Field

Group A

Group B

Total

P value

Grade 1

2 (6.7%)

0 (0.0%)

2

<0.001

Grade 2

13 (43.3%)

0 (0.0%)

13

Grade 3

11 (36.7%)

9 (30.0%)

20

Grade 4

4 (13.3%)

16 (53.3%)

20

Grade 5

0 (0.0%)

5 (16.7%)

5

Data were expressed as number of patients and percentages.
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Statistical analysis
Calculation of sample size was done using the operative
field bleeding score as the main variable. The calculation
determined 30 patients in each group. Statistical analysis
of the collected data was performed using SPSS version
20 (SPSS, Inc., Chicago, IL, USA). Quantitative data were
presented as mean and SD and were analyzed by using oneway analysis of variance test. Qualitative data was presented
as numbers and percentages and were analyzed using
χ2-test and Fisher’s exact test. P-value less than 0.05 was
considered significant.
Results
A total of 60 patients scheduled for ESS complaining of CRS
with sinonasal polyposis were included in the study between
February 2016 and June 2017. Demographic data, Operative
time and net blood loss are shown in (Table 2). There
was no significant difference between groups as regards to
demographic data (P>0.05).
Table 2 showed significant differences between groups
A and B as regard intraoperative blood loss. The mean
amount of blood loss during surgery was 155.50±64.93ml
for group A and 276.50±63.44 ml for group B with a p value
<0.001. The duration of surgery was significantly less in TA
group (41.77+9.03 min.) compared to the control group
(54.93+11.46 min).
Based on Boezaart's scale, the quality of the surgical field
showed significant difference between TA and control groups
(Table 3). The majority of patients in the intervention group
(80%) were in grade 2 and 3 while; the majority of the
patients in the control group (83.3%) were in grade 3 and 4.
Furthermore, no patients in the control group where in grade
1 and 2 while, 14 patients in the intervention group were in
grade 1 and 2 (46.7%). No patient in the intervention group
was in grade 5, while 5 patients in the control group were
in grade 5.
Early postoperative nausea was reported in 10% of
intervention group and 5 % of control group, showing no
significant differences between both groups. There were
no other side effects of TA reported as vomiting, confusion,
or thromboembolic events and there were no surgical
complications in both groups. All surgical procedures were
completed and there was no need to stop surgical progress
in all cases.
Discussion
Bleeding during ESS is the main surgical challenge for all
nasal endoscopiests. It may slow progress of surgery,
increase rate of complications or it may result in stop of the
procedure. Meanwhile, better visualization of the operative
field is mandatory to achieve the goals of surgery and to
avoid complications. [2,13]
Although the amount of blood loss in ESS is not that extensive
as in cardiac, gynecologic and orthopedic surgery, any
minimal bleeding impairs visualization and hence, increases
the incidence of complications and prolongs operative time.
[1,2,4]
Many tools were advocated to minimize intraoperative
bleeding and to improve visibility of the surgical field. The
commonly used methods are hypotensive anesthesia, local
vasoconstrictors, bipolar cauterization, elevation of the head
of the bed and the use of anti fibrinolytics. [8]
TA is a synthetic lysine analogue. It binds to lysine binding
sites on plasminogen and inhibits binding to fibrin, thus
blocks the process of fibrinolysis. TA proved efficacy in

orthopedic and cardiothoracic surgery. The current study
was designed to examine the safety and efficacy of using
large dose TA in ESS for CRS with sinonasal polyposis, as
regard intraoperative blood loss, operative time and quality
of surgical field. [9]
In our study, there was a significant decrease in intraoperative
bleed loss, significant improvement in surgical field quality,
and reduction in operative time in TA group compared to
placebo group.
In the field of otorhinolaryngology, the role of intravenous
TA in controlling blood loss during ESS is controversial. Some
authors proved the beneficial effect of TA, while others see
that it has no benefits.
Our results are in agreement with the results of Moise et
al., [10] who conducted a study in 2009 on 60 patients
candidates for ESS. The study group received 10 mg/kg TA
and the control group received normal saline. Intraoperative
and postoperative blood loss was decreased up to 50% in the
group received TA.
In 2011, the results of Moise et al. were verified by Alimian
and Mohseni. [11] They conducted a study on 84 patients
undergoing ESS and evaluated the effects of TA (10 mg/kg)
on hemorrhage and surgical field quality. They found that
intravenous TA effectively improved blood loss (184 ± 64 mL
in TA group compared to 312±75 mL in control group) and
the surgeon was more satisfied with the surgical field than
the placebo group.
Other studies were not in agreement with our study. In
2010 Mottaghi et al. [12] conducted a study on 50 patients
undergoing ESS. 25 patients in the study group received
500mg of intravenous TA and the control group received
normal saline. There was no significant difference between
both groups as regards intraoperative bleeding and surgeon
satisfaction scores.
In 2013 Langille et al. [13] published similar poor results. 28
patients with the diagnosis of CRS were enrolled in his study.
14 patients were in the TA group and 14 were in the saline
group. The intervention group received TA bolus (15 mg/kg)
then infusion (1 mg/kg/hr.) for the duration of the operation.
The control group received the equivalent volume of normal
saline. The use of TA was not associated with statistically
significant decrease in overall blood loss (201 vs 231 mL;
p=0.60) or significant improvement in surgical field quality
according to Wormald grading scale (5.84 vs 5.80; p=0.93).
The possible explanations for poor results obtained by
some authors may be the relatively small sample size in the
intervention groups (25 patients in the study of Mottaghi et
al. and 14 patients in the study of Langille et al.).
Another possible explanation may be attributed to the dose
regimen of TA. In the field of otorhinolaryngology, most
publications that used TA in ESS used relatively small doses
ranging between 5 and 25mg/kg. In our study we used a
large dose of TA (40mg/kg followed by continuous infusion
at a rate of 1mg/kg/hr.) as it is usually used in cardiac and
orthopedic surgery. [2,3]
Most literatures that investigated TA in ESS addressed
patients with a variable diagnoses. In our study, we targeted
patient complaining of allergic sinonasal polyposis. Patient
with CRS without polyps, antochoanal polyps, sinonasal
tumors or any other nasal lesions were excluded. We wanted
to avoid the effect of variations in pathology on outcomes
and duration of surgery.
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Postoperative nausea was greater in the intervention
group than in the control group, but the difference was not
significant (P>0.05). No significant difference was found
between the TA groups and the saline group as regard the
occurrence of thromboembolic events.
The main limitation of the present study is the limited
number of patients. Other studies with a larger scale of
patients are needed to confirm our results. In conclusion,
using large doses of TA in ESS for sinonasal polyposis is safe
and effective. Its use resulted in reduction of intraoperative
bleed loss, operative time and improvement of surgeon
satisfaction with the surgical field. Also, the use of large dose
of TA was well tolerated by patients and was not associated
with increased risk of side effects of TA. We recommend that
TA should be added to the routinely used drugs to control
bleeding during ESS.
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